These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 17316413

  • 1. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
    Millar EK, Tran K, Marr P, Graham PH.
    Pathol Int; 2007 Apr; 57(4):183-9. PubMed ID: 17316413
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J.
    Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
    [Abstract] [Full Text] [Related]

  • 6. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY.
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [Abstract] [Full Text] [Related]

  • 7. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia.
    Gillett CE, Lee AH, Millis RR, Barnes DM.
    J Pathol; 1998 Apr; 184(4):396-400. PubMed ID: 9664905
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemical evaluation of cyclin D1 in breast cancer.
    Bilalović N, Vranić S, Basić H, Tatarević A, Selak I.
    Croat Med J; 2005 Jun; 46(3):382-8. PubMed ID: 15861516
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH.
    Breast Cancer Res; 2004 Jun; 6(4):R308-15. PubMed ID: 15217497
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N, Peterse JL, Duchateau L, Robanus-Maandag EC, Bosch CA, Duval C, Pilotti S, van de Vijver MJ.
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High nuclear grade, frequent mitotic activity, cyclin D1 and p53 overexpression are associated with stromal invasion in mammary intracystic papillary carcinoma.
    Zhang C, Zhang P, Hao J, Quddus MR, Steinhoff MM, Sung CJ.
    Breast J; 2005 Feb; 11(1):2-8. PubMed ID: 15647071
    [Abstract] [Full Text] [Related]

  • 16. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S, Wang J, Bourne P, Yang Q, Tang P.
    Ann Clin Lab Sci; 2007 Feb; 37(2):127-34. PubMed ID: 17522367
    [Abstract] [Full Text] [Related]

  • 17. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.
    Clin Cancer Res; 2005 Mar 15; 11(6):2163-8. PubMed ID: 15788662
    [Abstract] [Full Text] [Related]

  • 18. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast.
    Alle KM, Henshall SM, Field AS, Sutherland RL.
    Clin Cancer Res; 1998 Apr 15; 4(4):847-54. PubMed ID: 9563877
    [Abstract] [Full Text] [Related]

  • 19. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 20. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
    Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC, Yu Y.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3660-6. PubMed ID: 14506155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.